Aclaris Therapeutics (ACRS) Tops Q1 EPS by 9c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.31), $0.09 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Stifel reports May 2026 client assets rose 16% year-over-year
• Commercial Metals (CMC) Tops Q3 EPS by 3c, Beats on Revenue